Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* EW HEALTHCARE PARTNERS FUND 2, L.P.	2. Issuer Name and Ticker or Trading Symbol TELA Bio, Inc. [ TELA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner _____ Officer (give title below) __X__ Other (specify below) See Footnote 2
(Last) (First) (Middle) 21 WATERWAY AVENUE, SUITE 225	3. Date of Earliest Transaction (MM/DD/YYYY) 3/23/2021
(Street) THE WOODLANDS, TX 77380 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.001 per share	3/23/2021		P		10000	A	$13.79	1534578	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	3/24/2021		P		2660	A	$13.94	1537238	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	3/25/2021		P		5000	A	$13.11	1542238	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	3/26/2021		P		37851	A	$12.88	1580089	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/8/2021		P		206	A	$13.67	1580295	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/12/2021		P		2893	A	$13.57	1583188	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/19/2021		P		625	A	$13.61	1583813	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/20/2021		P		4678	A	$13.54	1588491	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/21/2021		P		365	A	$13.59	1588856	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/22/2021		P		5000	A	$13.54	1593856	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/23/2021		P		5000	A	$13.51	1598856	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/27/2021		P		15000	A	$13.49	1613856	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	4/28/2021		P		200	A	$13.41	1614056	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	5/5/2021		P		7500	A	$13.28	1621556	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	5/6/2021		P		6499	A	$13.15	1628055	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	5/7/2021		P		7500	A	$13.15	1635555	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	5/10/2021		P		7500	A	$12.93	1643055	I	See footnotes ⁽¹⁾⁽²⁾
Common Stock, par value $0.001 per share	5/11/2021		P		7500	A	$12.75	1650555	I	See footnotes ⁽¹⁾⁽²⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	Shares shown above were the aggregate amount of shares purchased by EW Healthcare Partners Fund 2, L.P. ("Fund 2") and EW Healthcare Partners Fund 2-A, L.P. ("Fund 2-A") on each date set forth above. Exhibit 99.1 attached hereto shows the breakdown by each Fund on each purchase date and the total shares beneficially owned by each Fund following each such purchase:
(2)	EW Healthcare Partners Fund 2 GP, L.P. (the "EW Funds GP"), is the general partner of each of EW Healthcare Partners Fund 2, L.P. ("Fund 2'") and EW Healthcare Partners Fund 2-A, L.P. (''EW Fund 2-A" and together with EW Fund 2, the ''EW Funds"). EW Healthcare Partners Fund 2- UGP, LLC (the "General Partner") is the general partner of EW Funds GP. The General Parmer holds sole voting and dispositive power over the shares held by each of the EW Funds (the "Shares''). The managers of the General Parmer are Martin P. Sutter, Ron Eastman, Scott Bany and Petri Vainio (collectively, the ''Managers'') and may exercise voting and investment control over the Shares only by majority action of the Managers. Each individual Manager, the EW Funds GP and the General Partner disclaims beneficial ownership over the Shares except to the extent of his or its respective pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
EW HEALTHCARE PARTNERS FUND 2, L.P. 21 WATERWAY AVENUE, SUITE 225 THE WOODLANDS, TX 77380				See Footnote 2
EW HEALTHCARE PARTNERS FUND 2-A, L.P. 21 WATERWAY AVENUE, SUITE 225 THE WOODLANDS, TX 77380				See footnote 2
EW Healthcare Partners Fund 2 GP, L.P. 21 WATERWAY AVENUE, SUITE 225 THE WOODLANDS, TX 77380		X
EW Healthcare Partners Fund 2-UGP, L.P. 21 WATERWAY AVENUE, SUITE 225 THE WOODLANDS, TX 77380		X

Signatures
EW HEALTHCARE PARTNERS FUND 2, L.P., By: EW Healthcare Partners Fund 2 GP, L.P., its General Partner, By: EW Healthcare Partners Fund 2-UGP, LLC, its General Partner, By: Martin P. Sutter, Attorney-in-Fact, /s/ Martin P. Sutter		5/13/2021
^**Signature of Reporting Person		Date
EW HEALTHCARE PARTNERS FUND 2-A, L.P., By: EW Healthcare Partners Fund 2 GP, L.P., its General Partner, By: EW Healthcare Partners Fund 2-UGP, LLC, its General Partner, By: Martin P. Sutter, Attorney-in-Fact, /s/ Martin P. Sutter		5/13/2021
^**Signature of Reporting Person		Date
EW HEALTHCARE PARTNERS FUND 2 GP, L.P., By: EW Healthcare Partners Fund 2-UGP, LLC, its General Partner, By: Martin P. Sutter, Attorney-in-Fact, /s/ Martin P. Sutter		5/13/2021
^**Signature of Reporting Person		Date
EW HEALTHCARE PARTNERS FUND 2-UGP, LLC, By: Martin P. Sutter, Attorney-in-Fact, /s/ Martin P. Sutter		5/13/2021
^**Signature of Reporting Person		Date